1-Phenyl-2-ethyl-6,7-dimethoxy-1,2,3,4-tetrahydro-isochinolin | 20412-84-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 1-Phenyl-2-ethyl-6,7-dimethoxy-1,2,3,4-tetrahydro-isochinolin
• 英文别名: 2-ethyl-6,7-dimethoxy-1-phenyl-3,4-dihydro-1H-isoquinoline
• CAS: 20412-84-4
• 化学式: C₁₉H₂₃NO₂
• 分子量: 297.397
• InChiKey: BOPVPHQNRLLSLU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  21.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-(2,2-dimethoxyethyl)-N-[(3,4-dimethoxyphenyl)-phenylmethyl]-1-phenylmethanesulfonamide 在 盐酸 、 W-2 Raney nickel 作用下， 以 1,4-二氧六环 为溶剂， 反应 3.33h， 生成 1-Phenyl-2-ethyl-6,7-dimethoxy-1,2,3,4-tetrahydro-isochinolin
  参考文献：
  名称：

  N-苄基磺酰胺基1,2-二氢异喹啉的制备及其与阮内镍的反应。轻度新合成的异喹啉

  摘要：

  N-苄基磺酰胺基-1,2-二氢异喹啉与阮内镍反应以优异的收率和在温和的中性条件下提供异喹啉。

  DOI：

  10.1016/s0040-4039(97)00567-4

文献信息

• ARYLPIPERIDINYL AND ARYLPYRROLIDINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Niu Deqiang

  公开号：US20080279821A1

  公开（公告）日：2008-11-13

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及具有以下结构的化合物I，或其药用可接受的盐、酯或前药：这些化合物抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰乙型肝炎病毒的生命周期，并且还可用作抗病毒剂。本发明还涉及含有上述化合物的制药组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给受试者施用含有本发明化合物的制药组合物来治疗受试者的HCV感染的方法。
• Transition-Metal-Free Arylation of N-Alkyl-tetrahydroisoquinolines under Oxidative Conditions: A Convenient Synthesis of C1-Arylated Tetrahydro­isoquinoline Alkaloids
  作者：Kamal Singh、Satinder Kessar、Paramjit Singh、Pushpinder Singh、Manjot Kaur、Aanchal Batra

  DOI：10.1055/s-0034-1378337

  日期：——

  Abstract A simple protocol for the C1 arylation of tetrahydroisoquinolines with aryl Grignard reagents via diethyl azodicarboxylate (DEAD) mediated oxidative C–H activation under metal-free conditions has been developed. The target compounds, including some naturally occurring alkaloids, were obtained in moderate to good yields. A simple protocol for the C1 arylation of tetrahydroisoquinolines with

  摘要 已经开发了一种在无金属条件下通过偶氮二羧酸二乙酯（DEAD）介导的氧化CH活化四氢异喹啉与芳基格氏试剂进行C1芳基化的简单协议。以中等至良好的产率获得了目标化合物，包括一些天然存在的生物碱。 已经开发了一种在无金属条件下通过偶氮二羧酸二乙酯（DEAD）介导的氧化CH活化四氢异喹啉与芳基格氏试剂进行C1芳基化的简单协议。以中等至良好的产率获得了目标化合物，包括一些天然存在的生物碱。
• ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Niu Deqiang

  公开号：US20080317712A1

  公开（公告）日：2008-12-25

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.